Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Dermata Therapeutics Inc

DRMA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.46

▼ -7.01%

Market Cap $5.87M · Vol 64.33K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$5.87M

Micro Cap

Div Yield

N/A

EPS Growth

+72.92%

YoY

RSI (14)

58.10

Momentum

Beta

0.70

vs Market

52W High

$6.20

76.45% below

52W Low

$0.99

47.47% above

Volume

64.33K

Avg 124.56K

P/B

0.99

Price-to-book

ROE

N/A

Return on equity

Free Float

75.16%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Dermata Therapeutics Inc (DRMA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does DRMA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+32.73%

+10.61%

+18.70%

+13.18%

YTD

-37.07%

-74.87%

-99.18%

-99.99%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-7,558,560.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-132.63% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.99
P/FCF	N/A
EPS Growth	+72.92%
Outstanding Shares	4.02M

Technical Indicators

50-Day SMA	$1.26
200-Day SMA	$1.73
RSI (14)	58.10
Beta	0.70
52-Week High	$6.20
52-Week Low	$0.99

Volume Today	64.33K
Avg Daily Volume (30D)	124.56K
Relative Volume	0.52x
Volatility (10D)	153.42
Volatility (30D)	97.92
Free Float	75.16%

Analyst Consensus

BUY

Current Price $1.46

Mean Target $4.00

52W Low$0.99 52W High$6.20

Current

Target

$0.99 $6.20

Current Analyst target

+173.97% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG011DJT0Y1

ISINUS2498455045

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.